AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Genes & Diseases Article
PDF (3.2 MB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review Article | Open Access

Decrypting a path based approach for identifying the interplay between PI3K and GSK3 signaling cascade from the perspective of cancer

Abhijit Das, Barshana Bhattacharya, Souvik Roy( )
Department of Pharmacology, NSHM Knowledge Campus, Kolkata- Group of Institutions, Kolkata 700053, India

Peer review under responsibility of Chongqing Medical University.

Show Author Information

Abstract

Cancer is one of those leading diseases worldwide, which takes millions of lives every year. Researchers are continuously looking for specific approaches to eradicate the deadly disease, ensuring minimal adverse effects along with more therapeutic significance. Targeting of different aberrantly regulated signaling pathways, involved in cancer, is surely one of the revolutionary chemotherapeutic approach. In this instance, GSK3 and PI3K signaling cascades are considered as important role player for both the oncogenic activation and inactivation which further leads to cancer proliferation and metastasis. In this review, we have discussed the potential role of GSK3 and PI3K signaling in cancer, and we further established the crosstalk between PI3K and GSK3 signaling, through showcasing their cross activation, cross inhibition and convergence pathways in association with cancer. We also exhibited the effect of GSK3 on the efficacy of PI3K inhibitors to overcome the drug resistance and preventing the cell proliferation, metastasis in a combinatorial way with GSK3 inhibitors for a better treatment strategy in clinical settings.

Keywords

Drug resistanceCancerChemotherapyGSK3PI3K

References

1

Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.
Crossref Google Scholar
2

Mathur P, Sathishkumar K, Chaturvedi M, et al. Cancer statistics, 2020:report from national cancer registry programme, India. JCO Glob Oncol. 2020;6:1063-1075.
Crossref Google Scholar
3

Cohen MH, Williams G, Johnson JR, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res. 2002;8(5):935-942.
Google Scholar
4

Chiarini F, Evangelisti C, Lattanzi G, McCubrey JA, Martelli AM. Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells. Biochim Biophys Acta Mol Cell Res. 2019;1866(8):1322-1337.
Crossref Google Scholar
5

Jiang W, Ji M. Receptor tyrosine kinases in PI3K signaling: the therapeutic targets in cancer. Semin Cancer Biol. 2019;59:3-22.
Crossref Google Scholar
6

Revathidevi S, Munirajan AK. Akt in cancer: mediator and more. Semin Cancer Biol. 2019;59:80-91.
Crossref Google Scholar
7

Alzahrani AS. PI3K/Akt/mTOR inhibitors in cancer: at the bench and bedside. Semin Cancer Biol. 2019;59:125-132.
Crossref Google Scholar
8

Song M, Bode AM, Dong Z, Lee MH. AKT as a therapeutic target for cancer. Cancer Res. 2019;79(6):1019-1031.
Crossref Google Scholar
9

Nagini S, Sophia J, Mishra R. Glycogen synthase kinases: moonlighting proteins with theranostic potential in cancer. Semin Cancer Biol. 2019;56:25-36.
Crossref Google Scholar
10

MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17(1):9-26.
Crossref Google Scholar
11

Evangelisti C, Chiarini F, Paganelli F, Marmiroli S, Martelli AM. Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer. Biochim Biophys Acta Mol Cell Res. 2020;1867(4):118635.
Crossref Google Scholar
12

Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009;8(8):627-644.
Crossref Google Scholar
13

Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K pathway in human disease. Cell. 2017;170(4):605-635.
Crossref Google Scholar
14

Fritsch R, Downward J. SnapShot: class I PI3K isoform signaling. Cell. 2013;154(4):940.e1.
Crossref Google Scholar
15

Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol. 2010;11(5):329-341.
Crossref Google Scholar
16

Vanhaesebroeck B, Ali K, Bilancio A, Geering B, Foukas LC. Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem Sci. 2005;30(4):194-204.
Crossref Google Scholar
17

Guo H, German P, Bai S, et al. The PI3K/AKT pathway and renal cell carcinoma. J Genet Genomics. 2015;42(7):343-353.
Crossref Google Scholar
18

Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007;129(7):1261-1274.
Crossref Google Scholar
19

Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005;4(12):988-1004.
Crossref Google Scholar
20

Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene. 2005;24(50):7455-7464.
Crossref Google Scholar
21

Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol. 2010;28(6):1075-1083.
Crossref Google Scholar
22

Qiu W, Schönleben F, Li X, et al. PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer Res. 2006;12(5):1441-1446.
Crossref Google Scholar
23

Murugan A, Hong N, Fukui Y, Munirajan A, Tsuchida N. Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas. Int J Oncol. 2008;32(1):101-111.
Crossref Google Scholar
24

Jiang W, He T, Liu S, et al. The PIK3CA E542K and E545K mutations promote glycolysis and proliferation via induction of the β-catenin/SIRT3 signaling pathway in cervical cancer. J Hematol Oncol. 2018;11(1):139.
Crossref Google Scholar
25

Croessmann S, Sheehan JH, Lee KM, et al. PIK3CA C2 domain deletions hyperactivate phosphoinositide 3-kinase (PI3K), generate oncogene dependence, and are exquisitely sensitive to PI3K α inhibitors. Clin Cancer Res. 2018;24(6):1426-1435.
Crossref Google Scholar
26

Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA. 2005;102(3):802-807.
Crossref Google Scholar
27

Liaw D, Marsh DJ, Li J, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet. 1997;16(1):64-67.
Crossref Google Scholar
28

Chen CY, Chen J, He L, Stiles BL. PTEN: tumor suppressor and metabolic regulator. Front Endocrinol. 2018;9:338.
Crossref Google Scholar
29

Haddadi N, Lin Y, Travis G, Simpson AM, Nassif NT, McGowan EM. PTEN/PTENP1:'Regulating the regulator of RTK-dependent PI3K/Akt signalling', new targets for cancer therapy. Mol Cancer. 2018;17(1):37.
Crossref Google Scholar
30

Shen S, Liu H, Wang Y, et al. Long non-coding RNA CRNDE promotes gallbladder carcinoma carcinogenesis and as a scaffold of DMBT1 and C-IAP1 complexes to activating PI3K-AKT pathway. Oncotarget. 2016;7(45):72833-72844.
Crossref Google Scholar
31

Liu XX, Xiong HP, Huang JS, Qi K, Xu JJ. Highly expressed long non-coding RNA CRNDE promotes cell proliferation through PI3K/AKT signalling in non-small cell lung carcinoma. Clin Exp Pharmacol Physiol. 2017;44(8):895-902.
Crossref Google Scholar
32

Wang Y, Kong D. LncRNA GAS5 represses osteosarcoma cells growth and metastasis via sponging miR-203a. Cell Physiol Biochem. 2018;45(2):844-855.
Crossref Google Scholar
33

Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21(3):309-322.
Crossref Google Scholar
34

Sasaki T, Irie-Sasaki J, Jones RG, et al. Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. Science. 2000;287(5455):1040-1046.
Crossref Google Scholar
35

Liu X, Xu Y, Zhou Q, et al. PI3K in cancer: its structure, activation modes and role in shaping tumor microenvironment. Future Oncol. 2018;14(7):665-674.
Crossref Google Scholar
36

Xia C, Meng Q, Cao Z, Shi X, Jiang BH. Regulation of angiogenesis and tumor growth by p110 alpha and AKT1 via VEGF expression. J Cell Physiol. 2006;209(1):56-66.
Crossref Google Scholar
37

Fang J, Ding M, Yang L, Liu LZ, Jiang BH. PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. Cell Signal. 2007;19(12):2487-2497.
Crossref Google Scholar
38

Schmid MC, Avraamides CJ, Dippold HC, et al. Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3Kγ, A single convergent point promoting tumor inflammation and progression. Cancer Cell. 2011;19(6):715-727.
Crossref Google Scholar
39

Lu P, Ken T, Weaver VM, Werb Z. Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harbor Perspect Biol. 2011;3(12):a005058.
Crossref Google Scholar
40

Bhowmick NA, Chytil A, Plieth D, et al. TGF-ß signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science. 2004;303(5659):848-851.
Crossref Google Scholar
41

Wu X, Chen X, Zhou Q, et al. Hepatocyte growth factor activates tumor stromal fibroblasts to promote tumorigenesis in gastric cancer. Cancer Lett. 2013;335(1):128-135.
Crossref Google Scholar
42

Zhou R, Xu L, Ye M, Liao M, Du H, Chen H. Formononetin inhibits migration and invasion of MDA-MB-231 and 4T1 breast cancer cells by suppressing MMP-2 and MMP-9 through PI3K/AKT signaling pathways. Horm Metab Res. 2014;46(11):753-760.
Crossref Google Scholar
43

Levy J, Towers CG, Thorburn A. Targeting autophagy in cancer. Nat Rev Cancer. 2017;17(9):528-542.
Crossref Google Scholar
44

Karim MR, Fisher CR, Kapphahn RJ, Polanco JR, Ferrington DA. Investigating AKT activation and autophagy in immunoproteasome-deficient retinal cells. PLoS One. 2020;15(4):e0231212.
Crossref Google Scholar
45

Wang H, Liu Y, Wang D, et al. The upstream pathway of mTOR-mediated autophagy in liver diseases. Cells. 2019;8(12):1597.
Crossref Google Scholar
46

Wang B, Zhong Y, Li Q, Cui L, Huang G. Autophagy of macrophages is regulated by PI3k/Akt/mTOR signalling in the development of diabetic encephalopathy. Aging. 2018;10(10):2772-2782.
Crossref Google Scholar
47

Turco E, Fracchiolla D, Martens S. Recruitment and activation of the ULK1/Atg1 kinase complex in selective autophagy. J Mol Biol. 2020;432(1):123-134.
Crossref Google Scholar
48

Torii S, Yoshida T, Arakawa S, Honda S, Nakanishi A, Shimizu S. Identification of PPM1D as an essential Ulk1 phosphatase for genotoxic stress-induced autophagy. EMBO Rep. 2016;17(11):1552-1564.
Crossref Google Scholar
49

Kma L, Baruah TJ. The interplay of ROS and the PI3K/Akt pathway in autophagy regulation. Biotechnol Appl Biochem. 2022;69(1):248-264.
Crossref Google Scholar
50

Dubrovska A, Kim S, Salamone RJ, et al. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci USA. 2009;106(1):268-273.
Crossref Google Scholar
51

Koren S, Reavie L, Couto JP, et al. PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours. Nature. 2015;525(7567):114-118.
Crossref Google Scholar
52

van Veen JE, Scherzer M, Boshuizen J, et al. Mutationally-activated PI30-kinase-α promotes de-differentiation of lung tumors initiated by the BRAFV600E oncoprotein kinase. eLife. 2019;8:e43668.
Crossref Google Scholar
53

Riemer P, Rydenfelt M, Marks M, et al. Oncogenic β-catenin and PIK3CA instruct network states and cancer phenotypes in intestinal organoids. J Cell Biol. 2017;216(6):1567-1577.
Crossref Google Scholar
54

Chakrabarty A, Surendran S, Bhola NE, et al. The H1047R PIK3CA oncogene induces a senescence-like state, pleiotropy and acute HSP90 dependency in HER2+ mammary epithelial cells. Carcinogenesis. 2019;40(10):1179-1190.
Crossref Google Scholar
55

Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017;14(10):611-629.
Crossref Google Scholar
56

Scheel C, Eaton EN, Li SHJ, et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell. 2011;145(6):926-940.
Crossref Google Scholar
57

Katsuno Y, Meyer DS, Zhang Z, et al. Chronic TGF-β exposure drives stabilized EMT, tumor stemness, and cancer drug resistance with vulnerability to bitopic mTOR inhibition. Sci Signal. 2019;12(570):eaau8544.
Crossref Google Scholar
58

Kaneda MM, Cappello P, Nguyen AV, et al. Macrophage PI3Kγ drives pancreatic ductal adenocarcinoma progression. Cancer Discov. 2016;6(8):870-885.
Crossref Google Scholar
59

Spangle JM, Roberts TM, Zhao JJ. The emerging role of PI3K/AKT-mediated epigenetic regulation in cancer. Biochim Biophys Acta Rev Cancer. 2017;1868(1):123-131.
Crossref Google Scholar
60

Rahmani F, Ziaeemehr A, Shahidsales S, et al. Role of regulatory miRNAs of the PI3K/AKT/mTOR signaling in the pathogenesis of hepatocellular carcinoma. J Cell Physiol. 2020;235(5):4146-4152.
Crossref Google Scholar
61

Soltani A, Torki S, Ghahfarokhi MS, Jami MS, Ghatrehsamani M. Targeting the phosphoinositide 3-kinase/AKT pathways by small molecules and natural compounds as a therapeutic approach for breast cancer cells. Mol Biol Rep. 2019;46(5):4809-4816.
Crossref Google Scholar
62

Rocha G, Oliveira RR, Kaplan MAC, Gattass CR. 3β-Acetyl tormentic acid reverts MRP1/ABCC1 mediated cancer resistance through modulation of intracellular levels of GSH and inhibition of GST activity. Eur J Pharmacol. 2014;741:140-149.
Crossref Google Scholar
63

Choi E, Kim E, Kim JH, et al. AKT1-targeted proapoptotic activity of compound K in human breast cancer cells. J Ginseng Res. 2019;43(4):692-698.
Crossref Google Scholar
64

Adams JM, Cory S. The BCL-2 arbiters of apoptosis and their growing role as cancer targets. Cell Death Differ. 2018;25(1):27-36.
Crossref Google Scholar
65

Huang X, Wu Z, Mei Y, Wu M. XIAP inhibits autophagy via XIAP-mdm2-p53 signalling. EMBO J. 2013;32(16):2204-2216.
Crossref Google Scholar
66

Chen P, Zhang JY, Sha BB, et al. Luteolin inhibits cell proliferation and induces cell apoptosis via down-regulation of mitochondrial membrane potential in esophageal carcinoma cells EC1 and KYSE450. Oncotarget. 2017;8(16):27471-27480.
Crossref Google Scholar
67

Eberle J. Countering TRAIL resistance in melanoma. Cancers. 2019;11(5):656.
Crossref Google Scholar
68

Kumar S, Kushwaha PP, Gupta S. Emerging targets in cancer drug resistance. Cancer Drug Resist. 2019;2:161-177.
Crossref Google Scholar
69

Knuefermann C, Lu Y, Liu B, et al. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene. 2003;22(21):3205-3212.
Crossref Google Scholar
70

Si W, Shen J, Zheng H, Fan W. The role and mechanisms of action of microRNAs in cancer drug resistance. Clin Epigenet. 2019;11(1):25.
Crossref Google Scholar
71

Yao HB, Shaw PC, Wong CC, Wan DCC. Expression of glycogen synthase kinase-3 isoforms in mouse tissues and their transcription in the brain. J Chem Neuroanat. 2002;23(4):291-297.
Crossref Google Scholar
72

Sutherland C. What are the Bona fide GSK3 substrates? Int J Alzheimer's Dis. 2011;2011:505607.
Crossref Google Scholar
73

McCubrey JA, Fitzgerald TL, Yang LV, et al. Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells. Oncotarget. 2017;8(8):14221-14250.
Crossref Google Scholar
74

Luo J. Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. Cancer Lett. 2009;273(2):194-200.
Crossref Google Scholar
75

Woodgett JR. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J. 1990;9(8):2431-2438.
Crossref Google Scholar
76

Stamos JL, Chu MLH, Enos MD, Shah N, Weis WI. Structural basis of GSK-3 inhibition by N-terminal phosphorylation and by the Wnt receptor LRP6. eLife. 2014;3:e01998.
Crossref Google Scholar
77
GocAAl-HuseinBKatsanevasKTargeting Src-mediated Tyr216 phosphorylation and activation of GSK-3 in prostate cancer cells inhibit prostate cancer progression in vitro and in vivoOncotarget20145377578710.18632/oncotarget.1770

Goc A, Al-Husein B, Katsanevas K, et al. Targeting Src-mediated Tyr216 phosphorylation and activation of GSK-3 in prostate cancer cells inhibit prostate cancer progression in vitro and in vivo. Oncotarget. 2014;5(3):775-787.
Crossref Google Scholar
78

Jacobs KM, Bhave SR, Ferraro DJ, Jaboin JJ, Hallahan DE, Thotala D. GSK-3β: a bifunctional role in cell death pathways. Int J Cell Biol. 2012;2012:930710.
Crossref Google Scholar
79

McCubrey JA, Steelman LS, Bertrand FE, et al. GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget. 2014;5(10):2881-2911.
Crossref Google Scholar
80

Sayas CL, Ariaens A, Ponsioen B, Moolenaar WH. GSK-3 is activated by the tyrosine kinase Pyk2 during LPA1-mediated neurite retraction. Mol Biol Cell. 2006;17(4):1834-1844.
Crossref Google Scholar
81

Fang X, Yu SX, Lu Y, , Woodgett JR, Mills GB. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci USA. 2000;97(22):11960-11965.
Crossref Google Scholar
82

Tsujio I, Tanaka T, Kudo T, et al. Inactivation of glycogen synthase kinase-3 by protein kinase C delta: implications for regulation of tau phosphorylation. FEBS Lett. 2000;469(1):111-117.
Crossref Google Scholar
83

Takahashi-Yanaga F. Activator or inhibitor? GSK-3 as a new drug target. Biochem Pharmacol. 2013;86(2):191-199.
Crossref Google Scholar
84

Cervello M, Augello G, Cusimano A, et al. Pivotal roles of glycogen synthase-3 in hepatocellular carcinoma. Adv Biol Regul. 2017;65:59-76.
Crossref Google Scholar
85

Furuta T, Sabit H, Dong Y, et al. Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma. Oncotarget. 2017;8(14):22811-22824.
Crossref Google Scholar
86

Pal K, Cao Y, Gaisina IN, et al. Inhibition of GSK-3 induces differentiation and impaired glucose metabolism in renal cancer. Mol Cancer Therapeut. 2014;13(2):285-296.
Crossref Google Scholar
87

Chen S, Sun KX, Liu BL, Zong ZH, Zhao Y. The role of glycogen synthase kinase-3β (GSK-3β) in endometrial carcinoma: a carcinogenesis, progression, prognosis, and target therapy marker. Oncotarget. 2016;7(19):27538-27551.
Crossref Google Scholar
88

Abrahamsson AE, Geron I, Gotlib J, et al. Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. Proc Natl Acad Sci USA. 2009;106(10):3925-3929.
Crossref Google Scholar
89

Ma C, Wang J, Gao Y, et al. The role of glycogen synthase kinase 3beta in the transformation of epidermal cells. Cancer Res. 2007;67(16):7756-7764.
Crossref Google Scholar
90

Farago M, Dominguez I, Landesman-Bollag E, et al. Kinase-inactive glycogen synthase kinase 3beta promotes Wnt signaling and mammary tumorigenesis. Cancer Res. 2005;65(13):5792-5801.
Crossref Google Scholar
91

Mishra R, Nagini S, Rana A. Expression and inactivation of glycogen synthase kinase 3 alpha/beta and their association with the expression of cyclin D1 and p53 in oral squamous cell carcinoma progression. Mol Cancer. 2015;14:20.
Crossref Google Scholar
92

Mishra R. Glycogen synthase kinase 3 beta: can it be a target for oral cancer. Mol Cancer. 2010;9:144.
Crossref Google Scholar
93

Welcker M, Singer J, Loeb KR, et al. Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation. Mol Cell. 2003;12(2):381-392.
Crossref Google Scholar
94

Kitano A, Shimasaki T, Chikano Y, et al. Aberrant glycogen synthase kinase 3β is involved in pancreatic cancer cell invasion and resistance to therapy. PLoS One. 2013;8(2):e55289.
Crossref Google Scholar
95

Grimes CA, Jope RS. CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium. J Neurochem. 2001;78(6):1219-1232.
Crossref Google Scholar
96

Zhou F, Zhang L, van Laar T, Dam HV, Ten Dijke P. GSK3β inactivation induces apoptosis of leukemia cells by repressing the function of c-Myb. Mol Biol Cell. 2011;22(18):3533-3540.
Crossref Google Scholar
97

Linseman DA, Butts BD, Precht TA, et al. Glycogen synthase kinase-3beta phosphorylates bax and promotes its mitochondrial localization during neuronal apoptosis. J Neurosci. 2004;24(44):9993-10002.
Crossref Google Scholar
98

Klionsky DJ, Abdelmohsen K, Abe A, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016;12(1):1-222.
Crossref Google Scholar
99

Mancinelli R, Carpino G, Petrungaro S, et al. Multifaceted roles of GSK-3 in cancer and autophagy-related diseases. Oxid Med Cell Longev. 2017;2017:4629495.
Crossref Google Scholar
100

Stretton C, Hoffmann TM, Munson MJ, et al. GSK3-mediated raptor phosphorylation supports amino-acid-dependent mTORC1-directed signalling. Biochem J. 2015;470(2):207-221.
Crossref Google Scholar
101

Azoulay-Alfaguter I, Elya R, Avrahami L, Katz A, Eldar-Finkelman H. Combined regulation of mTORC1 and lysosomal acidification by GSK-3 suppresses autophagy and contributes to cancer cell growth. Oncogene. 2015;34(35):4613-4623.
Crossref Google Scholar
102

Marchand B, Arsenault D, Raymond-Fleury A, Boisvert FM, Boucher MJ. Glycogen synthase kinase-3 (GSK3) inhibition induces prosurvival autophagic signals in human pancreatic cancer cells. J Biol Chem. 2015;290(9):5592-5605.
Crossref Google Scholar
103

Sun A, Li C, Chen R, et al. GSK-3β controls autophagy by modulating LKB1-AMPK pathway in prostate cancer cells. Prostate. 2016;76(2):172-183.
Crossref Google Scholar
104

Inoki K, Ouyang H, Zhu T, et al. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell. 2006;126(5):955-968.
Crossref Google Scholar
105

Doble BW, Woodgett JR. Role of glycogen synthase kinase-3 in cell fate and epithelial-mesenchymal transitions. Cells Tissues Organs. 2007;185(1–3):73-84.
Crossref Google Scholar
106

Bachelder RE, Yoon SO, Franci C, de Herreros AG, Mercurio AM. Glycogen synthase kinase-3 is an endogenous inhibitor of Snail transcription: implications for the epithelial-mesenchymal transition. J Cell Biol. 2005;168(1):29-33.
Crossref Google Scholar
107

Lin G, Liu B, Meng Z, et al. miR-26a enhances invasive capacity by suppressing GSK3β in human lung cancer cells. Exp Cell Res. 2017;352(2):364-374.
Crossref Google Scholar
108

Tan Z, Zheng H, Liu X, et al. microRNA-1229 overexpression promotes cell proliferation and tumorigenicity and activates Wnt/β-catenin signaling in breast cancer. Oncotarget. 2016;7(17):24076-24087.
Crossref Google Scholar
109

Qiu HJ, Lu XH, Yang SS, Weng CY, Zhang EK, Chen FC. miR-769 promoted cell proliferation in human melanoma by suppressing GSK3B expression. Biomed Pharmacother. 2016;82:117-123.
Crossref Google Scholar
110

Yang HW, Liu GH, Liu YQ, et al. Over-expression of microRNA-940 promotes cell proliferation by targeting GSK3β and sFRP1 in human pancreatic carcinoma. Biomed Pharmacother. 2016;83:593-601.
Crossref Google Scholar
111

He K, Tong D, Zhang S, et al. miRNA-99b-3p functions as a potential tumor suppressor by targeting glycogen synthase kinase-3β in oral squamous cell carcinoma Tca-8113 cells. Int J Oncol. 2015;47(4):1528-1536.
Crossref Google Scholar
112

Zhou W, Li Y, Gou S, et al. miR-744 increases tumorigenicity of pancreatic cancer by activating Wnt/β-catenin pathway. Oncotarget. 2015;6(35):37557-37569.
Crossref Google Scholar
113

Chai S, Ng KY, Tong M, et al. Octamer 4/microRNA-1246 signaling axis drives Wnt/β-catenin activation in liver cancer stem cells. Hepatology. 2016;64(6):2062-2076.
Crossref Google Scholar
114

Yang Y, Lei T, Du S, et al. Nuclear GSK3β induces DNA double-strand break repair by phosphorylating 53BP1 in glioblastoma. Int J Oncol. 2018;52(3):709-720.
Crossref Google Scholar
115

Pyko IV, Nakada M, Sabit H, et al. Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling. Carcinogenesis. 2013;34(10):2206-2217.
Crossref Google Scholar
116

Gao C, Yuan X, Jiang Z, et al. Regulation of AKT phosphorylation by GSK3β and PTEN to control chemoresistance in breast cancer. Breast Cancer Res Treat. 2019;176(2):291-301.
Crossref Google Scholar
117

Fitzgerald TL, Lertpiriyapong K, Cocco L, et al. Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells. Adv Biol Regul. 2015;59:65-81.
Crossref Google Scholar
118

Ding L, Madamsetty VS, Kiers S, et al. Glycogen synthase kinase-3 inhibition sensitizes pancreatic cancer cells to chemotherapy by abrogating the TopBP1/ATR-mediated DNA damage response. Clin Cancer Res. 2019;25(21):6452-6462.
Crossref Google Scholar
119

Fu Y, Hu D, Qiu J, Xie X, Ye F, Lu WG. Overexpression of glycogen synthase kinase-3 in ovarian carcinoma cells with acquired paclitaxel resistance. Int J Gynecol Cancer. 2011;21(3):439-444.
Crossref Google Scholar
120

Matsumoto T, Yokoi A, Hashimura M, Oguri Y, Akiya M, Saegusa M. TGF-β-mediated LEFTY/Akt/GSK-3β/Snail axis modulates epithelial-mesenchymal transition and cancer stem cell properties in ovarian clear cell carcinomas. Mol Carcinog. 2018;57(8):957-967.
Crossref Google Scholar
121

Cai G, Wang J, Xin X, Ke Z, Luo J. Phosphorylation of glycogen synthase kinase-3 beta at serine 9 confers cisplatin resistance in ovarian cancer cells. Int J Oncol. 2007;31(3):657-662.
Crossref Google Scholar
122

Ito H, Ichiyanagi O, Naito S, et al. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition. BMC Cancer. 2016;16:393.
Crossref Google Scholar
123

Owonikoko TK, Harvey RD, Carthon B, et al. A phase I study of safety, pharmacokinetics, and pharmacodynamics of concurrent everolimus and buparlisib treatment in advanced solid tumors. Clin Cancer Res. 2020;26(11):2497-2505.
Crossref Google Scholar
124

Bardia A, Gounder M, Rodon J, et al. Phase ib study of combination therapy with MEK inhibitor binimetinib and phosphatidylinositol 3-kinase inhibitor buparlisib in patients with advanced solid tumors with RAS/RAF alterations. Oncol. 2020;25(1):e160-e169.
Crossref Google Scholar
125

Wen PY, Rodon JA, Mason W, et al. Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma. ESMO Open. 2020;5(4):e000673.
Crossref Google Scholar
126

Goodwin R, Jonker D, Chen E, et al. A phase Ib study of a PI3Kinase inhibitor BKM120 in combination with panitumumab in patients with KRAS wild-type advanced colorectal cancer. Invest N Drugs. 2020;38(4):1077-1084.
Crossref Google Scholar
127

Gelderblom H, Jones RL, George S, et al. Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study. Br J Cancer. 2020;122(8):1158-1165.
Crossref Google Scholar
128

Rosenthal M, Clement PM, Campone M, et al. Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study. ESMO Open. 2020;5(4):e000672.
Crossref Google Scholar
129

Assouline S, Amrein L, Aloyz R, et al. IND.216:a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia. Leuk Lymphoma. 2020;61(7):1653-1659.
Crossref Google Scholar
130

Garrido-Castro AC, Saura C, Barroso-Sousa R, et al. Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. Breast Cancer Res. 2020;22(1):120.
Crossref Google Scholar
131

Dummer R, Sandhu SK, Miller WH, et al. A phase II, multicenter study of encorafenib/binimetinib followed by a rational triple-combination after progression in patients with advanced BRAF V600-mutated melanoma (LOGIC2). J Clin Oncol. 2020;38(15_suppl):10022.
Crossref Google Scholar
132

Ramanathan RK, von Hoff DD, Eskens F, et al. Phase ib trial of the PI3K inhibitor copanlisib combined with the allosteric MEK inhibitor refametinib in patients with advanced cancer. Targeted Oncol. 2020;15(2):163-174.
Crossref Google Scholar
133

Morschhauser F, Machiels JP, Salles G, et al. On-target pharmacodynamic activity of the PI3K inhibitor copanlisib in paired biopsies from patients with malignant lymphoma and advanced solid tumors. Mol Cancer Therapeut. 2020;19(2):468-478.
Crossref Google Scholar
134

Song Y, Liu W, Niu Y, et al. 260P a phase I study of copanlisib, a pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor, in Chinese patients with relapsed indolent non-Hodgkin lymphoma (iNHL). Ann Oncol. 2020;31:S1344.
Crossref Google Scholar
135

Elmenier FM, Lasheen DS, Abouzid KAM. Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer. Eur J Med Chem. 2019;183:111718.
Crossref Google Scholar
136

Scott WJ, Hentemann MF, Rowley RB, et al. Discovery and SAR of novel 2, 3-dihydroimidazo[1, 2-c]quinazoline PI3K inhibitors: identification of copanlisib (BAY 80-6946). ChemMedChem. 2016;11(14):1517-1530.
Crossref Google Scholar
137

Rodon J, Dienstmann R, Serra V, Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol. 2013;10(3):143-153.
Crossref Google Scholar
138

Han F, Lin S, Liu P, et al. Discovery of a novel series of thienopyrimidine as highly potent and selective PI3K inhibitors. ACS Med Chem Lett. 2015;6(4):434-438.
Crossref Google Scholar
139

Zhang J, Lv X, Ma X, Hu Y. Discovery of a series of N-(5-(quinolin-6-yl)pyridin-3-yl)benzenesulfonamides as PI3K/mTOR dual inhibitors. Eur J Med Chem. 2017;127:509-520.
Crossref Google Scholar
140

Curigliano G, Shah RR. Safety and tolerability of phosphatidylinositol-3-kinase (PI3K) inhibitors in oncology. Drug Saf. 2019;42(2):247-262.
Crossref Google Scholar
141

Walz A, Ugolkov A, Chandra S, et al. Molecular pathways: revisiting glycogen synthase kinase-3β as a target for the treatment of cancer. Clin Cancer Res. 2017;23(8):1891-1897.
Crossref Google Scholar
142

Beurel E, Blivet-Van Eggelpoël MJ, Kornprobst M, et al. Glycogen synthase kinase-3 inhibitors augment TRAIL-induced apoptotic death in human hepatoma cells. Biochem Pharmacol. 2009;77(1):54-65.
Crossref Google Scholar
143

Zhang X, Castanotto D, Nam S, Horne D, Stein C. 6BIO enhances oligonucleotide activity in cells: a potential combinatorial anti-androgen receptor therapy in prostate cancer cells. Mol Ther. 2017;25(1):79-91.
Crossref Google Scholar
144

Domínguez JM, Fuertes A, Orozco L, del Monte-Millán M, Delgado E, Medina M. Evidence for irreversible inhibition of glycogen synthase kinase-3β by tideglusib. J Biol Chem. 2012;287(2):893-904.
Crossref Google Scholar
145

Gao Y, Ye DY, Zhou WC, Chu Y. The discovery of novel benzothiazinones as highly selective non-ATP competitive glycogen synthase kinase 3β inhibitors for the treatment of ovarian cancer. Eur J Med Chem. 2017;135:370-381.
Crossref Google Scholar
146

Eldar-Finkelman H, Licht-Murava A, Pietrokovski S, Eisenstein M. Substrate competitive GSK-3 inhibitors - strategy and implications. Biochim Biophys Acta. 2010;1804(3):598-603.
Crossref Google Scholar
147

Neumann T, Benajiba L, Göring S, Stegmaier K, Schmidt B. Evaluation of improved glycogen synthase kinase-3α inhibitors in models of acute myeloid leukemia. J Med Chem. 2015;58(22):8907-8919.
Crossref Google Scholar
148

Mai W, Kawakami K, Shakoori A, et al. Deregulated GSK3{beta} sustains gastrointestinal cancer cells survival by modulating human telomerase reverse transcriptase and telomerase. Clin Cancer Res. 2009;15(22):6810-6819.
Crossref Google Scholar
149

Elmaci İ, Altinoz MA. A metabolic inhibitory cocktail for grave cancers: metformin, pioglitazone and lithium combination in treatment of pancreatic cancer and glioblastoma multiforme. Biochem Genet. 2016;54(5):573-618.
Crossref Google Scholar
150

Palomo V, Martinez A. Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015). Expert Opin Ther Pat. 2017;27(6):657-666.
Crossref Google Scholar
151

Nwankwo N, Zhang Z, Wang T, et al. Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics. Invest N Drugs. 2013;31(3):653-660.
Crossref Google Scholar
152

Odia Y, Iwamoto FM, Moustakas A, et al. A phase II trial of enzastaurin (LY317615) in combination with bevacizumab in adults with recurrent malignant gliomas. J Neuro Oncol. 2016;127(1):127-135.
Crossref Google Scholar
153

Lynce F, Wang H, Petricoin EF, et al. A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies. Cancer Chemother Pharmacol. 2019;84(5):1145-1151.
Crossref Google Scholar
154

Algazi AP, Esteve-Puig R, Nosrati A, et al. Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma. Pigment Cell Melanoma Res. 2018;31(1):110-114.
Crossref Google Scholar
155

Fan X, Aalto Y, Sanko SG, Knuutila S, Klatzmann D, Castresana JS. Genetic profile, PTEN mutation and therapeutic role of PTEN in glioblastomas. Int J Oncol. 2002;21(5):1141-1150.
Crossref Google Scholar
156

Zundel W, Schindler C, Haas-Kogan D, et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 2000;14(4):391-396.
Crossref Google Scholar
157

Stambolic V, Woodgett JR. Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation. Biochem J. 1994;303(Pt 3):701-704. Pt 3.
Crossref Google Scholar
158

McCubrey JA, Steelman LS, Abrams SL, et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzym Regul. 2007;1773(8):1263-1284.
Crossref Google Scholar
159

Abubaker J, Jehan Z, Bavi P, et al. Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population. J Clin Endocrinol Metab. 2008;93(2):611-618.
Crossref Google Scholar
160

Vasko V, Saji M, Hardy E, et al. Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer. J Med Genet. 2004;41(3):161-170.
Crossref Google Scholar
161

Hemmings BA. Akt signaling: linking membrane events to life and death decisions. Science. 1997;275(5300):628-630.
Crossref Google Scholar
162

Salas TR, Kim J, Vakar-Lopez F, et al. Glycogen synthase kinase-3β is involved in the phosphorylation and suppression of androgen receptor activity. J Biol Chem. 2004;279(18):19191-19200.
Crossref Google Scholar
163

Wang Q, Horiatis D, Pinski J. Interleukin-6 inhibits the growth of prostate cancer xenografts in mice by the process of neuroendocrine differentiation. Int J Cancer. 2004;111(4):508-513.
Crossref Google Scholar
164

Mulholland DJ, Dedhar S, Wu H, Nelson CC. PTEN and GSK3β: key regulators of progression to androgen-independent prostate cancer. Oncogene. 2006;25(3):329-337.
Crossref Google Scholar
165
NickersonTChangFLorimerDSmeekensSPSawyersCLPollakMIn vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR)Cancer Res2001611662766280

Nickerson T, Chang F, Lorimer D, Smeekens SP, Sawyers CL, Pollak M. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res. 2001;61(16):6276-6280.
Google Scholar
166

Krueckl SL, Sikes RA, Edlund NM, et al. Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res. 2004;64(23):8620-8629.
Crossref Google Scholar
167

Verras M, Sun Z. Β-catenin is involved in insulin-like growth factor 1-mediated transactivation of the androgen receptor. Mol Endocrinol. 2005;19(2):391-398.
Crossref Google Scholar
168

Zhao H, Dupont J, Yakar S, Karas M, LeRoith D. PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells. Oncogene. 2004;23(3):786-794.
Crossref Google Scholar
169

Lee HC, Lin YZ, Lai YT, et al. Glycogen synthase kinase 3 beta in somites plays a role during the angiogenesis of zebrafish embryos. FEBS J. 2014;281(19):4367-4383.
Crossref Google Scholar
170

Zhang M, Zhang J, Chen X, Cho SJ, Chen X. Glycogen synthase kinase 3 promotes p53 mRNA translation via phosphorylation of RNPC1. Genes Dev. 2013;27(20):2246-2258.
Crossref Google Scholar
171

Koo J, Wu X, Mao Z, Khuri FR, Sun SY. Rictor undergoes glycogen synthase kinase 3 (GSK3)-dependent, FBXW7-mediated ubiquitination and proteasomal degradation. J Biol Chem. 2015;290(22):14120-14129.
Crossref Google Scholar
172

Gulen MF, Bulek K, Xiao H, et al. Inactivation of the enzyme GSK3α by the kinase IKKi promotes AKT-mTOR signaling pathway that mediates interleukin-1-induced Th17 cell maintenance. Immunity. 2012;37(5):800-812.
Crossref Google Scholar
173

Mak BC, Kenerson HL, Aicher LD, Barnes EA, Yeung RS. Aberrant beta-catenin signaling in tuberous sclerosis. Am J Pathol. 2005;167(1):107-116.
Crossref Google Scholar
174

Lin HK, Hu YC, Yang L, et al. Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers. J Biol Chem. 2003;278(51):50902-50907.
Crossref Google Scholar
175

Lin HK, Yeh S, Kang HY, Chang C. Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc Natl Acad Sci USA. 2001;98(13):7200-7205.
Crossref Google Scholar
176

Wen Y, Hu MC, Makino K, et al. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res. 2000;60(24):6841-6845.
Google Scholar
177

Park YL, Kim HP, Cho YW, et al. Activation of WNT/beta-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations. Int J Cancer. 2019;144(2):389-401.
Crossref Google Scholar
178

Laks DR, Oses-Prieto JA, Alvarado AG, et al. A molecular cascade modulates MAP1B and confers resistance to mTOR inhibition in human glioblastoma. Neuro Oncol. 2018;20(6):764-775.
Crossref Google Scholar
179

Chandarlapaty S, Sawai A, Scaltriti M, et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell. 2011;19(1):58-71.
Crossref Google Scholar
180

Zhuang G, Yu K, Jiang Z, et al. Phosphoproteomic analysis implicates the mTORC2-FoxO1 axis in VEGF signaling and feedback activation of receptor tyrosine kinases. Sci Signal. 2013;6(271):ra25.
Crossref Google Scholar
181

Ding Q, Xia W, Liu JC, et al. Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol Cell. 2005;19(2):159-170.
Crossref Google Scholar
182

Berezowska S, Schlegel J. Targeting ErbB receptors in high-grade glioma. Curr Pharmaceut Des. 2011;17(23):2468-2487.
Crossref Google Scholar
183

Okada K, Nogami A, Ishida S, et al. FLT3-ITD induces expression of Pim kinases through STAT5 to confer resistance to the PI3K/Akt pathway inhibitors on leukemic cells by enhancing the mTORC1/Mcl-1 pathway. Oncotarget. 2017;9(10):8870-8886.
Crossref Google Scholar
184

Britschgi A, Andraos R, Brinkhaus H, et al. JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer. Cancer Cell. 2012;22(6):796-811.
Crossref Google Scholar
185

Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 2005;5(5):375-386.
Crossref Google Scholar
186

Mui AL, Wakao H, O'Farrell AM, Harada N, Miyajima A. Interleukin-3, granulocyte-macrophage colony stimulating factor and interleukin-5 transduce signals through two STAT5 homologs. EMBO J. 1995;14(6):1166-1175.
Crossref Google Scholar
187

Elkabets M, Pazarentzos E, Juric D, et al. AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell. Cancer Cell. 2015;27(4):533-546.
Crossref Google Scholar
188

Badarni M, Prasad M, Balaban N, et al. Repression of AXL expression by AP-1/JNK blockage overcomes resistance to PI3Ka therapy. JCI Insight. 2019;5(8):e125341.
Crossref Google Scholar
189

Gjerdrum C, Tiron C, Høiby T, et al. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci USA. 2010;107(3):1124-1129.
Crossref Google Scholar
190

Vuoriluoto K, Haugen H, Kiviluoto S, et al. Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene. 2011;30(12):1436-1448.
Crossref Google Scholar
191

Paccez JD, Duncan K, Vava A, et al. Inactivation of GSK3β and activation of NF-κB pathway via Axl represents an important mediator of tumorigenesis in esophageal squamous cell carcinoma. Mol Biol Cell. 2015;26(5):821-831.
Crossref Google Scholar
Genes & Diseases
Volume 9 Issue 4,
July 2022
Pages 868-888
DOI: 10.1016/j.gendis.2021.12.025
Cite this article:
Das A, Bhattacharya B, Roy S. Decrypting a path based approach for identifying the interplay between PI3K and GSK3 signaling cascade from the perspective of cancer. Genes & Diseases, 2022, 9(4): 868-888. https://doi.org/10.1016/j.gendis.2021.12.025

287

Views

3

Downloads

2

Crossref

2

Web of Science

1

Scopus

0

CSCD

Altmetrics
Received: 24 November 2021
Revised: 21 December 2021
Accepted: 29 December 2021
Published: 22 February 2022
© 2022, Chongqing Medical University.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Return